Compare SYBT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYBT | MLYS |
|---|---|---|
| Founded | 1904 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2009 | 2023 |
| Metric | SYBT | MLYS |
|---|---|---|
| Price | $80.81 | $27.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $76.00 | $48.67 |
| AVG Volume (30 Days) | 207.5K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | 22.11 | ★ 37.43 |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $23,406,000.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | $65.16 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $12.59 |
| 52 Week High | $83.83 | $47.65 |
| Indicator | SYBT | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 52.43 |
| Support Level | $69.44 | $26.85 |
| Resistance Level | N/A | $31.26 |
| Average True Range (ATR) | 1.75 | 1.34 |
| MACD | 0.34 | -0.11 |
| Stochastic Oscillator | 79.02 | 26.69 |
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.